Texas 2015 84th Regular

Texas House Bill HB3651 Introduced / Fiscal Note

Filed 02/02/2025

Download
.pdf .doc .html
                    LEGISLATIVE BUDGET BOARD    Austin, Texas      FISCAL NOTE, 84TH LEGISLATIVE REGULAR SESSION            April 24, 2015      TO: Honorable Myra Crownover, Chair, House Committee on Public Health      FROM: Ursula Parks, Director, Legislative Budget Board     IN RE:HB3651 by Coleman (Relating to the manufacture, sale, distribution, possession, and use of drugs not approved by the United States Food and Drug Administration and the false representation that a substance is a drug approved by the United States Food and Drug Administration; creating criminal offenses.), As Introduced    No significant fiscal implication to the State is anticipated.  The bill would amend Chapter 431 of the Health and Safety Code to make it an offense to manufacture, sell, distribute, possess, or use a drug not approved by the U.S. Food and Drug Administration (FDA); exceptions are provided. The bill would make it an offense to 1) manufacture, sell, or distribute unapproved drugs, 2) make certain false claims, or 3) possess or use unapproved drugs. The Department of State Health Services and Department of Public Safety indicate that the provisions of the bill could be implemented within existing resources. This analysis assumes the bill's provisions would not result in a significant impact on state correctional populations, programs, or workloads. Local Government Impact A Class A misdemeanor is punishable by a fine of not more than $4,000, confinement in jail for a term not to exceed one year, or both. Costs associated with enforcement, prosecution, and confinement could likely be absorbed with existing resources. Revenue from fines imposed and collected is not anticipated to have a significant fiscal impact.    Source Agencies:405 Department of Public Safety, 537 State Health Services, Department of   LBB Staff:  UP, NB, WP, ADe, VJC, ESi, KVe    

LEGISLATIVE BUDGET BOARD
Austin, Texas
FISCAL NOTE, 84TH LEGISLATIVE REGULAR SESSION
April 24, 2015





  TO: Honorable Myra Crownover, Chair, House Committee on Public Health      FROM: Ursula Parks, Director, Legislative Budget Board     IN RE:HB3651 by Coleman (Relating to the manufacture, sale, distribution, possession, and use of drugs not approved by the United States Food and Drug Administration and the false representation that a substance is a drug approved by the United States Food and Drug Administration; creating criminal offenses.), As Introduced  

TO: Honorable Myra Crownover, Chair, House Committee on Public Health
FROM: Ursula Parks, Director, Legislative Budget Board
IN RE: HB3651 by Coleman (Relating to the manufacture, sale, distribution, possession, and use of drugs not approved by the United States Food and Drug Administration and the false representation that a substance is a drug approved by the United States Food and Drug Administration; creating criminal offenses.), As Introduced

 Honorable Myra Crownover, Chair, House Committee on Public Health 

 Honorable Myra Crownover, Chair, House Committee on Public Health 

 Ursula Parks, Director, Legislative Budget Board

 Ursula Parks, Director, Legislative Budget Board

HB3651 by Coleman (Relating to the manufacture, sale, distribution, possession, and use of drugs not approved by the United States Food and Drug Administration and the false representation that a substance is a drug approved by the United States Food and Drug Administration; creating criminal offenses.), As Introduced

HB3651 by Coleman (Relating to the manufacture, sale, distribution, possession, and use of drugs not approved by the United States Food and Drug Administration and the false representation that a substance is a drug approved by the United States Food and Drug Administration; creating criminal offenses.), As Introduced



No significant fiscal implication to the State is anticipated.

No significant fiscal implication to the State is anticipated.



The bill would amend Chapter 431 of the Health and Safety Code to make it an offense to manufacture, sell, distribute, possess, or use a drug not approved by the U.S. Food and Drug Administration (FDA); exceptions are provided. The bill would make it an offense to 1) manufacture, sell, or distribute unapproved drugs, 2) make certain false claims, or 3) possess or use unapproved drugs. The Department of State Health Services and Department of Public Safety indicate that the provisions of the bill could be implemented within existing resources. This analysis assumes the bill's provisions would not result in a significant impact on state correctional populations, programs, or workloads.

Local Government Impact

A Class A misdemeanor is punishable by a fine of not more than $4,000, confinement in jail for a term not to exceed one year, or both. Costs associated with enforcement, prosecution, and confinement could likely be absorbed with existing resources. Revenue from fines imposed and collected is not anticipated to have a significant fiscal impact.

Source Agencies: 405 Department of Public Safety, 537 State Health Services, Department of

405 Department of Public Safety, 537 State Health Services, Department of

LBB Staff: UP, NB, WP, ADe, VJC, ESi, KVe

 UP, NB, WP, ADe, VJC, ESi, KVe